event
On December 31, 2021, the application of Shanghai Lianying Medical Technology Co., Ltd. for listing on the science and innovation board has been accepted. It plans to publicly issue no more than 100 million shares and raise 12.48 billion yuan;
The prospectus shows that at present, China’s medical imaging equipment market is driven by medical demand and national policies. In the future, the market scale space is huge and is currently in the stage of continuous growth. Lianying medical is one of the enterprises with comprehensive product layout and strongest R & D strength in China, and its long-term development prospect is optimistic.
We hereby sort out the main points of the company’s prospectus for the reference of investors.
Investment elements
The technical barrier of medical imaging equipment is high, and the scale of China’s market continues to grow. With the rapid development of China’s economy, the aggravation of population aging, the improvement of people’s health awareness, the demand for medical and health care services continues to increase, and the demand for high-quality medical images in the Chinese market increases rapidly. At the same time, since the medical reform in 2012, relevant national departments have successively issued a series of policies related to the medical industry, aiming to optimize the level of medical services, encourage the implementation of hierarchical diagnosis and treatment, and promote the sinking of medical resources. Driven by market demand and policy dividends, China’s medical imaging equipment market will continue to grow. The market scale will reach 53.7 billion yuan in 2020 and the market space is expected to exceed 100 billion yuan in 2030.
The product layout is comprehensive, with significant share advantages of multiple tracks. According to different purposes and signals, medical imaging equipment can be divided into many different types of products. The company’s Mr, CT, PET / CT, PET / MR and Dr products rank at the forefront of the industry. Among them, Mr products rank first in China’s new market share, CT products rank first in China’s new market share, PET / CT and PET / MR products rank first in China’s new market share, and Dr and mobile Dr products rank second and first in China’s new market share respectively, Significant market share leading edge.
Reserve global excellent R & D talents with strong comprehensive R & D capability. The company has absorbed industry talents from the perspective of globalization and established a professional team with senior industry management and technical experience. By the end of the reporting period, the company had nearly 2000 R & D personnel, accounting for more than 35% of the total number of employees; More than 1700 people in the company have master’s or doctor’s degrees, and more than 350 people have overseas education background or work experience. At present, the proportion of self research of the company ranks in the forefront of the industry, and the main core components of each product line are self-developed and self-produced.
The three-dimensional layout of marketing network and the improvement of after-sales service system. Combined with direct selling and distribution mode, the company has created a diversified three-dimensional marketing system covering domestic and foreign markets, from third-class hospitals to grass-roots institutions. The company’s products have been settled in nearly 900 class III hospitals. The top 10 medical institutions in China are all company users, and there are 49 company users in the top 50 medical institutions. In terms of overseas markets, the company has established sales networks in the United States, Japan and other countries and regions around the world. And established a detail oriented and excellence oriented after-sales team to provide customers with all-round after-sales comprehensive services.
Purpose of the raised funds: Based on the existing core technologies and products, promote the core technology research and development of existing product lines and new products ultrasonic equipment; Build a new industrialization base for the production of high-end XR, CT, PET / CT, Mr and PET / MR products; It is planned to add, reconstruct and expand marketing service centers and after-sales service centers at home and abroad, and carry out academic conferences and promotion activities; To comprehensively upgrade the company’s information construction, including IT infrastructure, information security, data governance center, financial operation system, sales operation system, production operation system, product R & D system, etc; Used to supplement working capital.
Risk statement
Risk of product R & D failure or failure to industrialization; Risk of implementing centralized procurement policy; Cooperation risk under distribution mode; Risks of international operation and business development; Procurement risk of core components.
